A Phase 1 Dose Escalation Study Evaluating The Safety And Tolerability Of Pf-06804103 In Patients With Human Epidermal Growth Factor Receptor 2 (her2) Positive Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 24 Nov 2017
At a glance
- Drugs PF-06804103 (Primary)
- Indications Breast cancer; Gastric cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 19 Nov 2017 Planned End Date changed from 27 Sep 2020 to 19 Aug 2020.
- 19 Nov 2017 Planned primary completion date changed from 27 Sep 2020 to 19 Aug 2020.
- 19 Nov 2017 Status changed from not yet recruiting to recruiting.